Show simple item record

dc.contributor.authorFuertes, Antonio
dc.contributor.authorOry, Fernando de 
dc.contributor.authorMinguito, Teodora 
dc.contributor.authorEchevarria, Juan Emilio 
dc.contributor.authorMosquera, Maria del Mar 
dc.date.accessioned2020-06-16T08:32:45Z
dc.date.available2020-06-16T08:32:45Z
dc.date.issued2014-03
dc.identifier.citationAPMIS . 2014 Mar;122(3):223-9.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10447
dc.description.abstractThe aim of this study was to evaluate enzyme immunoassays (EIA) (Euroimmun, Lübeck, Germany) and chemiluminiscent immunoassays (CLIA) (Diasorin, Saluggia, Italy) in their application to detect B19V-IgM and -IgG. For this purpose, one hundred and ninety samples were studied. Of them, 101 came from recent infection cases (B19V-specific IgM (86) and/or PCR (87), 42 from past infections, 18 from non-infected, and 29 from other viral recent infections (Epstein-Barr virus, measles, and rubella). Samples were characterized by capture (for IgM), or indirect (for IgG) EIA (Biotrin, Dublin, Ireland); indeterminate samples were classified by indirect immunofluorescence (IIF) (Biotrin). All the samples were used for testing IgM assays, and all but the cases from other viral infections were used for IgG tests. For IgM, CLIA, and EIA identified 76 and 62 of 86 IgM positives, respectively (sensitivity 88.4% and 72.1%). Considering B19V IgM negative samples, negative result was obtained in 95 and 92 of 104, being the specificity values of CLIA and EIA 91.3% and 88.5%, respectively. For IgG, CLIA and EIA identified correctly 114 and 115 of the 122 positive samples (sensitivity 93.4% and 94.3%, respectively), and 39 and 36 of 39 negative samples (specificity 100% and 92.3%). As conclusion, CLIA methods can be used in clinical laboratories as adequate alternatives to the well-established Biotrin EIAs.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAntibodies, Viral es_ES
dc.subject.meshEpstein-Barr Virus Infections es_ES
dc.subject.meshFluorescent Antibody Technique, Indirect es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunoenzyme Techniques es_ES
dc.subject.meshImmunoglobulin G es_ES
dc.subject.meshImmunoglobulin M es_ES
dc.subject.meshMeasles es_ES
dc.subject.meshParvoviridae Infections es_ES
dc.subject.meshParvovirus B19, Humanes_ES
dc.subject.meshRubella es_ES
dc.subject.meshSensitivity and Specificity es_ES
dc.subject.meshSpecimen Handling es_ES
dc.titleComparative evaluation of tests for detection of parvovirus B19 IgG and IgM.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID23763266es_ES
dc.format.volume122es_ES
dc.format.number3es_ES
dc.format.page223-9es_ES
dc.identifier.doi10.1111/apm.12127es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1600-0463es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/apm.12127es_ES
dc.identifier.journalAPMIS : acta pathologica, microbiologica, et immunologica Scandinavicaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional